68Ga-RM2 PET/MRI在前列腺癌生化复发且常规影像阴性患者中的前瞻性评估
32例前列腺癌生化复发且常规影像(CT或MRI及99mTc-MDP骨扫描)阴性的男性患者接受68Ga-RM2 PET/MRI检查,PET检出率为71.8%(23/32),同期MRI检出11/32。PET阳性组PSA速度高于PET阴性组(2.51±2.16 vs 0.32±0.59 ng/mL/y,P=0.006)。作者认为68Ga-RM2 PET可用于评估GRPr表达,是定位病灶有前景的PET显像剂。
要点
- 68Ga-RM2 PET在常规影像阴性的前列腺癌生化复发患者中检出率为71.8%(23/32)。
- 同期MRI仅检出11/32例兼容复发的前列腺癌表现。
- PET阳性组PSA速度2.51±2.16 ng/mL/y,高于阴性组0.32±0.59 ng/mL/y(P=0.006)。
核心结论
- 68Ga-RM2 PET可用于评估前列腺癌生化复发患者的GRPr表达。
- 多部位高摄取兼容肿瘤病灶,提示68Ga-RM2是定位常规影像阴性生化复发患者病灶的有前景PET显像剂。
研究设计与样本
- 前瞻性研究,纳入32例前列腺癌生化复发且常规影像阴性的男性患者,年龄59-83岁(均值±标准差68.7±6.4岁)。
- 注射68Ga-RM2 133.2-151.7 MBq(均值140.6±7.4 MBq)后40-69分钟(均值50.5±6.8分钟)开始显像,使用飞行时间同步PET/MRI扫描仪,采集T1加权、T2加权和弥散加权图像。
主要发现
- 所有患者入组前PSA升高(范围0.3-119.0 ng/mL;均值10.1±21.3 ng/mL),常规影像(CT或MRI及99mTc-亚甲基二膦酸盐骨扫描)阴性。
- 68Ga-RM2 PET检出率为71.8%,在32例参与者中检出23例复发性前列腺癌。
- 同期MRI在32例患者中检出11例兼容复发性前列腺癌的表现。
- PET阴性患者PSA速度为0.32±0.59 ng/mL/y(范围0.04-1.9 ng/mL/y),PET阳性患者为2.51±2.16 ng/mL/y(范围0.13-8.68 ng/mL/y),P=0.006。
关键数值与推荐
- 68Ga-RM2 PET检出率71.8%(23/32),同期MRI检出11/32。
- PET阴性组PSA速度0.32±0.59 ng/mL/y vs PET阳性组2.51±2.16 ng/mL/y,P=0.006。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
68Ga-labeled DOTA-4-amino-1-carboxymethyl-piperidine-d-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2 (68Ga-RM2) is a synthetic bombesin receptor antagonist that targets gastrin-releasing peptide receptor (GRPr). GRPr proteins are highly overexpressed in several human tumors, including prostate cancer (PCa). We present data from the use of 68Ga-RM2 in patients with biochemical recurrence (BCR) of PCa and negative findings on conventional imaging. Methods: We enrolled 32 men with BCR of PCa, who were 59-83 y old (mean ± SD, 68.7 ± 6.4 y). Imaging started at 40-69 min (mean, 50.5 ± 6.8 min) after injection of 133.2-151.7 MBq (mean, 140.6 ± 7.4 MBq) of 68Ga-RM2 using a time-of-flight-enabled simultaneous PET/MRI scanner. T1-weighted, T2-weighted, and diffusion-weighted images were acquired. Results: All patients had a rising level of prostate-specific antigen (PSA) (range, 0.3-119.0 ng/mL; mean, 10.1 ± 21.3 ng/mL) and negative findings on conventional imaging (CT or MRI, and a 99mTc-methylene diphosphonate bone scan) before enrollment. The observed 68Ga-RM2 PET detection rate was 71.8%. 68Ga-RM2 PET identified recurrent PCa in 23 of the 32 participants, whereas the simultaneous MRI scan identified findings compatible with recurrent PCa in 11 of the 32 patients. PSA velocity was 0.32 ± 0.59 ng/mL/y (range, 0.04-1.9 ng/mL/y) in patients with negative PET findings and 2.51 ± 2.16 ng/mL/y (range, 0.13-8.68 ng/mL/y) in patients with positive PET findings (P = 0.006). Conclusion:68Ga-RM2 PET can be used for assessment of GRPr expression in patients with BCR of PCa. High uptake in multiple areas compatible with cancer lesions suggests that 68Ga-RM2 is a promising PET radiopharmaceutical for localization of disease in patients with BCR of PCa and negative findings on conventional imaging.
引用
- Minamimoto R, Sonni I, Hancock S, et al. Prospective Evaluation of 68Ga-RM2 PET/MRI in Patients with Biochemical Recurrence of Prostate Cancer and Negative Findings on Conventional Imaging. J Nucl Med. 2017. PMID: 29084827. doi:10.2967/jnumed.117.197624
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。